The DOI matches its Crossref record; 316 of the 318 references it cites were found in a registry or an index, and 1 are not checked yet.
Combination strategies to maximize the benefits of cancer immunotherapy
Open accessAbstract
Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy (ACT) have revolutionized cancer treatment, especially in patients whose disease was otherwise considered incurable. However, primary and secondary resistance to single agent immunotherapy often results in treatment failure, and only a minority of patients experience long-term benefits. This review article will discuss the relationship between cancer immune response and mechanisms of resistance to immunotherapy. It will also provide a comprehensive review on the latest clinical status of combination therapies (e.g., immunotherapy with chemotherapy, radiation therapy and targeted therapy), and discuss combination therapies approved by the US Food and Drug Administration. It will provide an overview of therapies targeting cytokines and other soluble immunoregulatory factors, ACT, virotherapy, innate immune modifiers and cancer vaccines, as well as combination therapies that exploit alternative immune targets and other therapeutic modalities. Finally, this review will include the stimulating insights from the 2020 China Immuno-Oncology Workshop co-organized by the Chinese American Hematologist and Oncologist Network (CAHON), the China National Medical Product Administration (NMPA) and Tsinghua University School of Medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Accumulating evidence indicates that chemotherapy, radiotherapy, angiogenesis inhibitor, stimulator of interferon genes (STING) agonist, fecal microbiota transplantation (FMT), epigenetic modulators, or other immunomodulators could synergize α-PD-1/PD-L1, by enhancing cancer antigen release, APC function, or effector activity [22–31].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 1×
“Two coronavirus (COVID-19) mRNA vaccines approved in the US are both RNA vaccines formulated in lipid nanoparticles [285, 286].”
BackgroundEfficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119 · cited 1×
“Two coronavirus (COVID-19) mRNA vaccines approved in the US are both RNA vaccines formulated in lipid nanoparticles [285, 286].”
BackgroundCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607 · cited 1×
“Pembrolizumab + pemetrexed /platinum First‐line non‐squamous NSCLC May 10, 2017 [50, 296]”
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Research works printed but not linked: 1
- Shalabi H, Shah NN, Fry TJ, Yates B, Delbrook C, Yuan C, Stetler-Stevenson M, Ramakrishna S. Intensification of lymphodepletion optimizes CAR re-treatment efficacy. Blood. 2017;130(Supplement 1):3889–3889.
Cited by
Sorted by citations
Items 201–300 of 663
Perioperative immunotherapy for esophageal squamous cell carcinoma
Wei, D. D., Fang, J. M., Wang, H., Chen, J., Kong, S., Jiang, Y., & Jiang, Y. Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1330785 · Cited by 17
Açıkgül, F. Ç., Duran, N., Kutlu, T., Ay, E., Tek, E., & Bayraktar, S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e36223 · Cited by 17
Recent Advances in Silica-Based Nanomaterials for Enhanced Tumor Imaging and Therapy
Zhang, J., Liu, Z., Zhang, Z., Yang, H. Y., Wang, H., Yang, Z., Xu, Y., Li, S., & Yang, D. (2024) · ACS Applied Bio Materials · doi:10.1021/acsabm.4c01318 · Cited by 17
Liu, Y., Chen, J., Li, X., Fan, Y., Peng, C. Y., Ye, X., Wang, Y. A., & Xie, X. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107577 · Cited by 17
Dermatologic toxicities related to cancer immunotherapy
Vaez-Gharamaleki, Y., Akbarzadeh, M. A., Jadidi‐Niaragh, F., Mahmoodpoor, A., Sanaie, S., & Hosseini, M. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.102021 · Cited by 17
Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy
Albarrán-Artahona, V., Laguna, J. C., Gorría, T., Torres-Jiménez, J., Pascal, M., & Mezquita, L. (2022) · Diagnostics · doi:10.3390/diagnostics12092091 · Cited by 17
Youssef, R., Maniar, R., Khan, J., & Mesa, H. A. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45120609 · Cited by 17
Cancer Immunotherapy—An Overview
Kulkarni, P., Do, D., Shrestha, S., Leach, B., & Salgia, R. (2025) · Cancer treatment and research · doi:10.1007/978-3-031-97242-3_1 · Cited by 16
Banstola, A., Pandit, M., Duwa, R., Chang, J., Jeong, J., & Yook, S. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10379 · Cited by 16
Exosomes as drug delivery system in gastrointestinal cancer
Xie, F., Huang, Y., Zhan, Y., & Bao, L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1101823 · Cited by 16
Recent advances of engineered oncolytic viruses-based combination therapy for liver cancer
Zhang, J., Xiao, Y., Zhang, L., Yang, Y., Zhang, L., & Liang, F. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-023-04817-w · Cited by 17
Sferruzza, G., Consoli, S., Dono, F., Evangelista, G., Giugno, A., Pronello, E., Rollo, E., Romozzi, M., Rossi, L., & Pensato, U. (2024) · Neurological Sciences · doi:10.1007/s10072-024-07350-w · Cited by 16
The future of cancer vaccines against colorectal cancer
Jia, W., Shen, X., Guo, Z., Cheng, X., & Zhao, R. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2341744 · Cited by 16
Immune checkpoint inhibitors targeting PD-1/PD-L1 in the treatment of human lymphomas
Ribatti, D., Cazzato, G., Tamma, R., Annese, T., Ingravallo, G., & Specchia, G. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1420920 · Cited by 16
Siao, C.-L., Chang, W.-C., Chen, C.-H., Lee, Y., & Lai, Y. (2024) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2024.102686 · Cited by 16
Xu, R., Lin, P., Zheng, J., Lin, Y., Mai, Z., Lu, Y., Xu, C., Zhou, Z., Li, C., & Zhao, X. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101386 · Cited by 16
Utilizing chemotherapy-induced tumor RNA nanoparticles to improve cancer chemoimmunotherapy
Su, L., Pan, W., Li, X., Zhou, X., Ma, X., & Min, Y. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.12.039 · Cited by 16
Reprogramming the tumor microenvironment to improve the efficacy of cancer immunotherapies
Faraj, J. A., Al-Athari, A. J. H., Mohie, S. E. D., Kadhim, I. K., Jawad, N. M., Abbas, W. J., & Jalil, A. T. (2022) · Medical Oncology · doi:10.1007/s12032-022-01842-5 · Cited by 16
Jiang, P., Chen, C., Tian, J., Yang, F., Jiang, Z., Hu, A., & Liu, B. (2024) · Academic Radiology · doi:10.1016/j.acra.2024.09.061 · Cited by 15
Immune checkpoint inhibitors in gynecologic oncology: Current status and perspectives
Yanaihara, N., Tse, K. Y., Lee, S. J., Yoo, J. G., & Wilailak, S. (2025) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.70280 · Cited by 15
ClinicalOmicsDB: exploring molecular associations of oncology drug responses in clinical trials
Moon, C. I., Elizarraras, J. M., Lei, J. T., Jia, B., & Zhang, B. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad871 · Cited by 15
Peng, H., Deng, J., Jiang, S. B., & Timmerman, R. D. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1357790 · Cited by 15
Cao, X., Wan, S., Wu, B., Liu, Z., Xu, L., Ding, Y. J., & Huang, H. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c01277 · Cited by 17
Zhu, Z., Cao, S., Li, H., Zhang, Z., Lu, Q., Li, H., Shen, L., Wang, Z., Yang, N., Yu, J., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113603 · Cited by 15
T-Cell Engager Therapy in Prostate Cancer: Molecular Insights into a New Frontier in Immunotherapy
Kwon, W., & Joung, J. Y. (2025) · Cancers · doi:10.3390/cancers17111820 · Cited by 15
Neoantigen-Based Immunotherapy in Lung Cancer: Advances, Challenges and Prospects
Li, X., Zhu, Y., Xue, Y., Chen, T., Sun, X., & Shi, H. (2025) · Cancers · doi:10.3390/cancers17121953 · Cited by 15
Riemann, D., Turzer, S., Ganchev, G., Schütte, W., Seliger, B., & Möller, M. (2023) · Biomolecules · doi:10.3390/biom13020190 · Cited by 15
Lin, J., Zhou, Y., Li, C., Li, B., Hao, H., Tian, F., Li, H., Liu, Z., Wang, G., Shen, X., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122703 · Cited by 14
Geng, S., Fang, B., Wang, K., Wang, F., Zhou, Y., Hou, Y., Iqbal, M. Z., Chen, Y., & Yu, Z. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c11594 · Cited by 14
Covalent Plant Natural Product that Potentiates Antitumor Immunity
Takemoto, M., Delghandi, S., Abo, M., Yurimoto, K., Odagi, M., Singh, V. P., Wang, J., Nakagawa, R., Sato, S., Takemoto, Y., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c17837 · Cited by 14
Challenges in the preclinical design and assessment of CAR-T cells
Tomai, R. A., Rivas, J. D. L., Fetică, B., Bergantim, R., Filipić, B., Gagić, Ž., Nikolic, K. M., Gulei, D., Kegyes, D., Nistor, M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1564998 · Cited by 14
Tumor Cell-Intrinsic BTLA Receptor Inhibits the Proliferation of Tumor Cells via ERK1/2
Cheng, T., Liu, Y., Yan, H., Xi, Y., Duan, L., Wang, Y., Zhang, T., Gu, Y., Wang, X., Wu, C., et al. (2022) · Cells · doi:10.3390/cells11244021 · Cited by 14
Self-citationStructures and Applications of Nucleic Acid-Based Micelles for Cancer Therapy
Kim, H., & Kwak, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021592 · Cited by 14
Zhai, S., You, Z., Li, J., Zheng, B., Zhao, X., Jiang, W., Su, D. S., Wang, H., Han, C., & Lu, K. (2025) · ACS Nano · doi:10.1021/acsnano.5c06188 · Cited by 13
Hu, C., Li, Q., Xiang, L., Luo, Y., Li, S., An, J., Yu, X., Zhang, G., Chen, Y., Wang, Y., et al. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.11.043 · Cited by 13
Zhou, Y., Wang, F., Li, G., Xu, J., Zhang, J., Gullen, E. A., Yang, J., & Wang, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1340307 · Cited by 13
Immunotherapy in the Treatment of Cancer: Today and Tomorrow
Şi̇mşek, G. Ö. (2024) · Current Molecular Biology Reports · doi:10.1007/s40610-024-00161-0 · Cited by 13
Zhu, X., Li, Y., Liu, H., Wang, Y., Sun, R., Jiang, Z., Hou, C., Hou, X., Huang, S., Zhang, H., et al. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.05.007 · Cited by 13
Self-citationPiezo-catalytic immunotherapy: mechanisms and feasibility in cancer treatment
Chen, Z., Sang, L., Bian, D., Liu, Y., & Bai, Z. (2025) · Theranostics · doi:10.7150/thno.114676 · Cited by 13
Generative AI - Assisted Adaptive Cancer Therapy
Derbal, Y. (2025) · Cancer Control · doi:10.1177/10732748251349919 · Cited by 13
Recent advances in tumour microenvironment impact immunotherapy resistance in gastric cancer
Sun, Q., Li, S., Lou, J. J., Wang, X., & Xu, X. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104837 · Cited by 13
Schofield, H.-L., Fabrizio, V. A., Braniecki, S. H., Pelletier, W., Eissa, H., Murphy, B., Chewning, J. H., Barton, K. D., Embry, L. M., Levine, J. E., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.06.027 · Cited by 13
Xu, C., Khanal, S., Pierson, N. A., Quiroz, J., Kochert, B. A., Yang, X., Wylie, D., & Strulson, C. A. (2022) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-022-04366-z · Cited by 13
The cell stress and immunity cycle in cancer: Toward next generation of cancer immunotherapy
Laureano, R. S., Vanmeerbeek, I., Sprooten, J., Govaerts, J., Naulaerts, S., & Garg, A. D. (2023) · Immunological Reviews · doi:10.1111/imr.13287 · Cited by 13
Chen, L., Chu, Y., Ye, Z., Gu, S., Hu, Y., He, J., & Shen, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1337129 · Cited by 13
Wan, Y., Ding, J., Jia, Z., Hong, Y., Tian, G., Zheng, S., Pan, P., Wang, J., & Liang, H. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e32965 · Cited by 13
Chu, X., Tian, W., Ning, J., & Zhou, R. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae137 · Cited by 12
Immunotherapy in Oncogene-Addicted NSCLC: Evidence and Therapeutic Approaches
Foffano, L., Bertoli, E., Bortolot, M., Torresan, S., Carlo, E. D., Stanzione, B., Conte, A. D., Puglisi, F., Spina, M., & Bearz, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020583 · Cited by 12
Zhang, X., Shi, C., Liu, Q., Zhong, Y., Zhu, L., & Zhao, Y. (2025) · Journal of Materials Chemistry B · doi:10.1039/d4tb02125h · Cited by 12
Wang, L., Jiang, Y., Sun, C.-H., Chen, P., & Ding, Y. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189285 · Cited by 12
Kim, Y., Park, W., Kim, S., Kim, E. H., Choi, J., Jang, H., Ryu, Y., Hwang, J., Kim, M., Cho, Y. J., et al. (2026) · ACS Nano · doi:10.1021/acsnano.5c20535 · Cited by 12
Gupta, K., Jones, J. C., Farias, V., Mackeyev, Y., Singh, P. K., Quiñones‐Hinojosa, A., & Krishnan, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.840241 · Cited by 12
The expression pattern of Immune checkpoints after chemo/radiotherapy in the tumor microenvironment
Hassanian, H., Asadzadeh, Z., Baghbanzadeh, A., Derakhshani, A., Dufour, A., Khosroshahi, N. R., Najafi, S., Brunetti, O., Silvestris, N., & Baradaran, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.938063 · Cited by 12
Targeting Epigenetic Mechanisms: A Boon for Cancer Immunotherapy
Parab, A., Bhatt, L. K., & Omri, A. (2023) · Biomedicines · doi:10.3390/biomedicines11010169 · Cited by 12
Zhou, Y., Dong, L., Dai, L., Hu, S., Sun, Y., Wu, Y., Pan, T., & Li, X. (2023) · Frontiers in Surgery · doi:10.3389/fsurg.2023.1133335 · Cited by 12
Feng, X., Meng, X., Tang, D., Guo, S., Liao, Q., Chen, J., Xie, Q., Liu, F., Fang, Y., Sun, C., et al. (2023) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2023.07.003 · Cited by 12
Zou, W., Luo, X., Gao, M., Chang, Y., Wan, X., Yu, S., Wu, Y., Wang, A., Fenical, W., Wei, Z., et al. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16054 · Cited by 12
Chen, C., & Li, Y. (2023) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2023.03.04 · Cited by 12
Wang, Y., Li, S., Peng, Y., Ma, W., Wang, Y., & Li, W. (2023) · Cancer Innovation · doi:10.1002/cai2.59 · Cited by 11
Schäfer, R. A., Guo, Q., & Yang, R. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad659 · Cited by 11
Zhen, S., Wang, W., Qin, G., Lu, T., Li, Y., & Zhang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1316778 · Cited by 11
Mitra, A., Roy, R., & Paul, S. (2024) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.4c04798 · Cited by 11
Xia, B., Qiu, L., Yue, J., Si, J., & Zhang, H. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189190 · Cited by 11
Comprehensive review of signaling pathways and therapeutic targets in gastrointestinal cancers
Ji, P., Chen, T., Li, C. R., Zhang, J., Li, X., & Zhu, H. P. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104586 · Cited by 11
Application of nanomedicines in tumor immunotherapy
Gao, Z., Wan, D., Luo, M., & Wei, X. (2024) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjae055 · Cited by 11
Recent Advances in Polysaccharide-Based Hydrogels for Tumor Immunotherapy
Zhou, Y., Chen, K., Cheng, H., & Zhang, S. (2025) · Gels · doi:10.3390/gels11030152 · Cited by 11
Wei, X., Luo, Z.-W., Zhang, G., Lin, Y.-A., An, L., An, L.-K., He, X., Su, J., & Zhang, C. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.111048 · Cited by 11
Domenico, P. D., Gagliardi, F., Roncelli, F., Snider, S., & Mortini, P. (2025) · Journal of Neuro-Oncology · doi:10.1007/s11060-025-04989-z · Cited by 11
Expanding horizons of cancer immunotherapy: hopes and hurdles
Sonar, P. V., Singh, A. K., Mandadi, S., & Sharma, N. K. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1511560 · Cited by 11
Ferreira, J. S. L., Vareda, J. P., Oliveira, A. S. R., Barbosa, J. S., Bastos, F., Mendonça, P. V., & Fonseca, A. C. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb00268k · Cited by 11
Yang, W.-C., Wei, M., Shen, Y., Huang, C., & Kuo, S. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01173-3 · Cited by 11
Yu, T., Zhao, X., Dong, C., Lu, H., Wang, Y., Luo, X., & Gao, Z. (2025) · CytoJournal · doi:10.25259/cytojournal_273_2024 · Cited by 11
Rupp, L., Resag, A., Potkrajcic, V., Warm, V., Wehner, R., Jöhrens, K., Bösmüller, H. C., Eckert, F., & Schmitz, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1185197 · Cited by 11
Chen, Y., Wen, H., Li, Y., Han, Y., Tan, J., Guo, C., Cai, C., Liu, P., Peng, Y., Liu, Y., et al. (2023) · Biological Procedures Online · doi:10.1186/s12575-023-00201-6 · Cited by 11
Rouf, S. C., Moore, C., Saha, D., Nguyen, D. T. D., Bleile, M., Timmerman, R. D., Peng, H., & Jiang, S. B. (2024) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2024.111974 · Cited by 11
Practical immunomodulatory landscape of glioblastoma multiforme (GBM) therapy
Norollahi, S. E., Yousefi, B., Nejatifar, F., Yousefzadeh-Chabok, S., Rashidy‐Pour, A., & Samadani, A. A. (2024) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-024-00240-4 · Cited by 11
Chen, S., Wei, H., Zhao, W., Jiang, W., Ning, R., Zhou, S., Tan, L., Wang, H., Su, C., He, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1059995 · Cited by 11
Radiotherapy plus immune checkpoint inhibitor in prostate cancer
Li, T., Qian, X., Liu, J., Xue, F., Luo, J., Yao, G., Yan, J., Liu, X., Xiao, B., & Li, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1210673 · Cited by 10
Improving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptides
Fu, Q., Luo, Y., Li, J., Zhang, P., Tang, S., Song, X., Fu, J., Liu, M., Mo, R., Wei, M. Q., et al. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2385654 · Cited by 10
Immune monitoring of neoadjuvant chemo-immunotherapy for triple-negative breast cancer
Syeda, M. F., Santos, R. A., Sousa, L. M., Paiva, A. R., Branco, N. C., Pereira, T. C., Sousa, G., & Rodrigues‐Santos, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1654748 · Cited by 10
Tumor heterogeneity: development, mechanisms, and therapeutic implications
Zhang, J., Li, H., Ru, S., Feng, H., Guo, J., Sun, D., Xiang, T., Xu, D., & Luo, Y. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02749-7 · Cited by 12
Ye, L., Zhao, G., Ma, J., Gan, Q., Luo, N., Pan, D., Chen, C., Chen, X., & Ning, S. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02769-3 · Cited by 10
Zhang, X., Wang, K., Gao, Z., Wu, Z., Liu, W., Li, J., Gao, H., Wei, J., Ding, D., & Zheng, W. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202302118 · Cited by 10
Universal DNA-Based Sensing Toolbox for Programming Cell Functions
Ma, P., Huang, F.-W., Xie, Y.-Q., Li, H., Li, H., Ye, B., & Yin, B. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c11232 · Cited by 10
Adaptive Control of Tumor Growth
Derbal, Y. (2024) · Cancer Control · doi:10.1177/10732748241230869 · Cited by 10
Sun, J., Wang, P., Yi, Z., Wu, Y., Wei, Y., Fang, H., Song, D., Chen, Y., Du, H., Huang, J., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0484 · Cited by 10
Holdase/Foldase Mimetic Nanochaperone Improves Antibody‐Based Cancer Immunotherapy
Zhang, Y., Fu, H., Chen, J., Xu, L., An, Y., Ma, R., Zhu, C., Liu, Y., Ma, F., & Shi, L. (2022) · Small Methods · doi:10.1002/smtd.202201051 · Cited by 10
Focus on mechano-immunology: new direction in cancer treatment
Zhao, L., Gui, Y., & Deng, X. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002224 · Cited by 10
Lan, H., Liu, H., Hou, H., Zhang, C., Zhu, J., Zhou, N., & Zhang, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1539616 · Cited by 9
Self-citationUrias, E., Lee, J., Weil, C. R., Roach, E. A., Lloyd, S. A. J., Hashibe, M., Facciabene, A., Maity, A. M., & Tao, R. (2025) · BMJ Oncology · doi:10.1136/bmjonc-2025-000732 · Cited by 9
Song, L., Qi, G., Shi, W., Zeng, Q., Qin, Y., Wang, Z., Li, W., Song, Z., Zhang, A., & Lu, H. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011944 · Cited by 9
Liu, D., Xiao, L. X., Wu, Y., Yue, C., Li, M., Sun, Y., & Yang, C. J. (2025) · Small Methods · doi:10.1002/smtd.202500770 · Cited by 9
Self-citationLiu, J., Qu, C., Liu, Y., Gongye, X., Zhang, M., Ma, T., He, W., Wang, H., Chen, X., Xia, P., et al. (2025) · Nature Cell Biology · doi:10.1038/s41556-025-01815-6 · Cited by 9
Pandey, A., Rai, S. K., Ma, L., Higa, L., Khadka, V. S., Yang, H., & Deng, Y. (2026) · Advanced Science · doi:10.1002/advs.202518960 · Cited by 9
Deng, T., Wang, F., Zhang, L., Ning, T., Sun, Y., Ge, S., Bai, M., Lü, Y., Li, H., & Ba, Y. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03743-0 · Cited by 9
Subbarayan, R., Srinivasan, D., Balakrishnan, R., Kumar, A., Usmani, S. S., & Srivastava, N. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2024.05.001 · Cited by 9
Amin, M. U., Ali, S., Engelhardt, K. H., Nasrullah, U., Preis, E., Schaefer, J., Pfeilschifter, J. M., & Bakowsky, U. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114503 · Cited by 9
Amato, L., Rosa, C. D., Rosa, V. D., Hossein, H. H. S., Ariano, A., Franco, P., Nele, V., Capaldo, S., Guida, G. D., Sepe, F., et al. (2024) · Cancers · doi:10.3390/cancers16183151 · Cited by 9
Li, J., Luo, Y., Fu, Q., Tang, S., Zhang, P., Frazer, I. H., Liu, X., Wang, T., & Ni, G. (2025) · Scientific Reports · doi:10.1038/s41598-025-87687-0 · Cited by 9
Wan, Y., Wang, Z., Yang, N., & Liu, F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.911961 · Cited by 9
Metadata
- Authors
- Zhu, S., Zhang, T., Zheng, L., Liu, H., Song, W., Liu, D., Li, Z., & Pan, C.-X.
- Affiliations
- Beijing Chao-Yang Hospital, Capital Medical University (CN)
- Duke University (US)
- Johns Hopkins University (US)
- University of Chicago (US)
- New York Medical College (US)
- The Ohio State University (US)
- Harvard University (US)
- Corresponding author
- Li, Zihai
- Pan, Chong-xian
- Venue
- Journal of Hematology & Oncology
- Published
- 2021-09-27
- Volume
- 14
- Issue
- 1
- Pages
- 156-156
- ISSN
- 1756-8722 (ISSN-L)
- PMC
- PMC8475356
- OpenAlex
- W3202901824
- Cited by
- 654
- References
- 318
- Citations by year
- 2026: 78 · 2025: 163 · 2024: 206 · 2023: 127 · 2022: 77 · 2021: 2
- FWCI
- 12.51
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal of Hematology & Oncology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Touro Scholar (Touro College) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Tsinghua University
- National Cancer Institute (P50CA062924)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- cancer immunotherapy, combination therapy, immune checkpoint blockade, adoptive immunotherapy, immunotherapy resistance, cancer vaccines, virotherapy, cytokine-targeted therapy, combination chemotherapy, radiation therapy combination, combination targeted therapy
- MeSH terms
- Immune Checkpoint Inhibitors, Animals, Combined Modality Therapy, Humans, Immunotherapy, Neoplasms, Cancer Vaccines, Oncolytic Virotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
